Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Net Cash Flow: 2012-2024

Historic Net Cash Flow for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $7.5 million.

  • Amphastar Pharmaceuticals' Net Cash Flow rose 1017.85% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.9 million, marking a year-over-year increase of 130.59%. This contributed to the annual value of $7.5 million for FY2024, which is 165.13% up from last year.
  • Amphastar Pharmaceuticals' Net Cash Flow amounted to $7.5 million in FY2024, which was up 165.13% from -$11.5 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Net Cash Flow high stood at $32.3 million for FY2021, and its period low was -$11.5 million during FY2023.
  • Its 3-year average for Net Cash Flow is $8.6 million, with a median of $7.5 million in 2024.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Net Cash Flow soared by 248.27% in 2020 and then slumped by 138.44% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Net Cash Flow (Yearly) stood at $18.6 million in 2020, then skyrocketed by 73.63% to $32.3 million in 2021, then fell by 7.24% to $30.0 million in 2022, then slumped by 138.44% to -$11.5 million in 2023, then soared by 165.13% to $7.5 million in 2024.